Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH),
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback